VENTAVIS Drug Patent Profile
✉ Email this page to a colleague
When do Ventavis patents expire, and what generic alternatives are available?
Ventavis is a drug marketed by Actelion and is included in one NDA.
The generic ingredient in VENTAVIS is iloprost. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloprost profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VENTAVIS?
- What are the global sales for VENTAVIS?
- What is Average Wholesale Price for VENTAVIS?
Summary for VENTAVIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 33 |
| Patent Applications: | 2,334 |
| Drug Prices: | Drug price information for VENTAVIS |
| What excipients (inactive ingredients) are in VENTAVIS? | VENTAVIS excipients list |
| DailyMed Link: | VENTAVIS at DailyMed |
Recent Clinical Trials for VENTAVIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hamad Medical Corporation | Phase 2 |
| Actelion | Phase 4 |
| National Cancer Institute (NCI) | Phase 1 |
Pharmacology for VENTAVIS
| Drug Class | Prostacycline |
US Patents and Regulatory Information for VENTAVIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-002 | Dec 8, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actelion | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-001 | Dec 29, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actelion | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-003 | Aug 7, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VENTAVIS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | Ventavis | iloprost | EMEA/H/C/000474 Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms. |
Authorised | no | no | no | 2003-09-15 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
